Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-779788 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-779788 or Placebo (Arm 1) | ACTIVE_COMPARATOR | - |
| BMS-779788 or Placebo (Arm 2) | ACTIVE_COMPARATOR | - |
| BMS-779788 or Placebo (Arm 3) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-779788 | DRUG | Oral Solution, Oral, 1 mg, Once daily, 7 days |
| Placebo | DRUG | Oral Solution, Oral, 0 mg, Once daily, 7 days |
Inclusion Criteria: * Men and women (not of child bearing potential) ages 18 to 45 * Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations Exclusion Criteria: * Women of child bearin...
BMS-779788 is an investigational small molecule being developed for the treatment of atherosclerosis, a condition characterized by the buildup of plaque in the arteries. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BMS-779788 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and pharmacology of this investigational drug.
BMS-779788 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. Its safety and efficacy are still being evaluated in early-stage clinical trials.
BMS-779788 has one completed Phase 1 clinical trial, identified as NCT00836602. This was a multiple-dose study in healthy subjects to evaluate the safety, pharmacokinetics, and pharmacodynamics of the drug. The trial enrolled 25 participants in Australia.
No, BMS-779788 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug has not completed the clinical trials and regulatory review processes required for marketing approval.